Following non-submission
AWMSG advice |
||
| Status: Not endorsed (Statement of Advice) | ||
In the absence of a submission from the holder of the marketing authorisation, emtricitabine/tenofovir (Truvada®) cannot be endorsed for use within NHS Wales for the treatment of HIV-1 infected adolescents, with NRTI resistance or toxicities precluding the use of first line agents, aged 12 to < 18 years. |
||
|
||
Medicine details |
||
| Medicine name | emtricitabine / tenofovir (Truvada®) | |
| Formulation | Film-coated tablet | |
| Reference number | 3463 | |
| Indication | Treatment of HIV-1 infected adolescents, with NRTI resistance or toxicities precluding the use of first line agents, aged 12 to < 18 years |
|
| Company | Gilead Sciences Ltd | |
| BNF chapter | Infections | |
| Assessment type | Non-submission | |
| Status | Not endorsed (Statement of Advice) | |
| Date of issue | 12/07/2017 | |